144 related articles for article (PubMed ID: 23836346)
1. Ziv-aflibercept (Zaltrap) for metastatic colorectal cancer.
Med Lett Drugs Ther; 2013 Apr; 55(1415):e36. PubMed ID: 23836346
[No Abstract] [Full Text] [Related]
2. Ziv-aflibercept (Zaltrap) for the treatment of metastatic colorectal cancer.
Perkins SL; Cole SW
Ann Pharmacother; 2014 Jan; 48(1):93-8. PubMed ID: 24259608
[TBL] [Abstract][Full Text] [Related]
3. Targeted therapy for metastatic colorectal cancer: role of aflibercept.
Mitchell EP
Clin Colorectal Cancer; 2013 Jun; 12(2):73-85. PubMed ID: 23102896
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetic analysis of free and bound aflibercept in patients with advanced solid tumors.
Thai HT; Veyrat-Follet C; Mentré F; Comets E
Cancer Chemother Pharmacol; 2013 Jul; 72(1):167-80. PubMed ID: 23673444
[TBL] [Abstract][Full Text] [Related]
5. [New data confirm it: Zaltrap prolongs survival of all sub-populations with metastatic colorectal cancer ].
Rev Med Suisse; 2014 May; 10(431):1114-5. PubMed ID: 24941681
[No Abstract] [Full Text] [Related]
6. Phase II clinical and pharmacokinetic study of aflibercept in patients with previously treated metastatic colorectal cancer.
Tang PA; Cohen SJ; Kollmannsberger C; Bjarnason G; Virik K; MacKenzie MJ; Lourenco L; Wang L; Chen A; Moore MJ
Clin Cancer Res; 2012 Nov; 18(21):6023-31. PubMed ID: 22977191
[TBL] [Abstract][Full Text] [Related]
7. Ziv-aflibercept: a novel angiogenesis inhibitor for the treatment of metastatic colorectal cancer.
Chung C; Pherwani N
Am J Health Syst Pharm; 2013 Nov; 70(21):1887-96. PubMed ID: 24128964
[TBL] [Abstract][Full Text] [Related]
8. Aflibercept: A Review in Metastatic Colorectal Cancer.
Syed YY; McKeage K
Drugs; 2015 Aug; 75(12):1435-45. PubMed ID: 26220913
[TBL] [Abstract][Full Text] [Related]
9. [Aflibercept (Zaltrap(®)) approved in metastatic colorectal cancer].
André T; Chibaudel B
Bull Cancer; 2013 Oct; 100(10):1023-5. PubMed ID: 24047539
[TBL] [Abstract][Full Text] [Related]
10. [New molecular-targeted agents for colorectal cancer - regorafenib and aflibercept].
Kato S
Gan To Kagaku Ryoho; 2013 Jan; 40(1):6-9. PubMed ID: 23306912
[TBL] [Abstract][Full Text] [Related]
11. [Opinion DGVS the IQWiG report for early benefit assessment of aflibercept for the treatment of metastatic colorectal cancer according to § 35a SGB V on May 29, 2013].
Z Gastroenterol; 2013 Aug; 51(8):1019-22. PubMed ID: 24298632
[No Abstract] [Full Text] [Related]
12. FDA approves aflibercept (Zaltrap) for metastatic colorectal cancer.
Oncology (Williston Park); 2012 Sep; 26(9):842, 873. PubMed ID: 23061342
[No Abstract] [Full Text] [Related]
13. A preclinical and clinical review of aflibercept for the management of cancer.
Gaya A; Tse V
Cancer Treat Rev; 2012 Aug; 38(5):484-93. PubMed ID: 22264850
[TBL] [Abstract][Full Text] [Related]
14. Aflibercept in lung cancer.
Neal JW; Wakelee HA
Expert Opin Biol Ther; 2013 Jan; 13(1):115-20. PubMed ID: 23199019
[TBL] [Abstract][Full Text] [Related]
15. Ziv-aflibercept: binding to more than VEGF-A--does more matter?
Clarke JM; Hurwitz HI
Nat Rev Clin Oncol; 2013 Jan; 10(1):10-1. PubMed ID: 23149898
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and pharmacodynamic evaluation of aflibercept for the treatment of colorectal cancer.
Sanz-Garcia E; Saurí T; Tabernero J; Macarulla T
Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):995-1004. PubMed ID: 25988772
[TBL] [Abstract][Full Text] [Related]
17. Emerging VEGF-receptor inhibitors for colorectal cancer.
Martinelli E; Troiani T; Morgillo F; Orditura M; De Vita F; Belli G; Ciardiello F
Expert Opin Emerg Drugs; 2013 Mar; 18(1):25-37. PubMed ID: 23216053
[TBL] [Abstract][Full Text] [Related]
18. An oncology nurses' guide to new targeted agents for metastatic colorectal cancer.
McIntyre K
Clin J Oncol Nurs; 2015 Oct; 19(5):571-9. PubMed ID: 26414575
[TBL] [Abstract][Full Text] [Related]
19. Understanding the mechanisms of action of antiangiogenic agents in metastatic colorectal cancer: a clinician's perspective.
Clarke JM; Hurwitz HI; Rangwala F
Cancer Treat Rev; 2014 Oct; 40(9):1065-72. PubMed ID: 25047778
[TBL] [Abstract][Full Text] [Related]
20. Is there a benefit from addiction to anti-VEGF therapy in patients with colorectal cancer?
Saif MW
Anticancer Res; 2013 Jun; 33(6):2377-80. PubMed ID: 23749885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
